- Source : Business Wire
- Date : 2019-03-14
- Companies : EnClear Therapies, Inc.
EnClear Therapies Announces Seed Funding and Senior R&D Appointment
CAMBRIDGE, Mass.--(BUSINESS WIRE)--EnClear Therapies, a biotechnology company developing device-based therapies for the treatment of neurodegenerative disease, today announced that the company had secured approximately $2 million in seed funding and that it has hired Kevin Kalish as Vice President of Research and Development.
“EnClear is moving forward rapidly in developing our unique approach to treating Amyotrophic Lateral Sclerosis. Based on our progress to date, we believe we have a pathway that could see our lead program in human clinical trials in two years,” said Anthony DePasqua, Chief Executive Officer and Co-founder, EnClear Therapies. “I’m gratified to have completed this round of seed financing with partners who believe in our technology and share our vision of delivering meaningful therapies to patients living with neurological diseases.”
Partners in the seed financing included Thiel Capital, Bioverge, Sanford Biosciences and Christian Angermayer‘s Presight Capital.
“EnClear’s approach to ALS has the potential to be the first treatment option to slow, and potentially even halt, this devastating disease,” said Rick Gibb, Co-founder and Chief Operating Officer, Bioverge, Inc. “Bioverge is excited to partner with such an exemplary team and help support its groundbreaking mission and technology.”
“The addition of Kevin Kalish to our leadership team fills a key role during this critical phase in the growth of EnClear,” said Mr. DePasqua. “As the leader of our research and development function, Kevin brings deep industry and technical knowledge along with the passion to deliver significant new therapies to improve outcomes for patients.”
“At EnClear we have an amazing opportunity to positively impact patients’ lives,” said Kevin Kalish. “Our understanding of the mechanisms and progression of neurological diseases, such as ALS, has drastically improved over the past several years. EnClear Therapies is well positioned to take that learning and apply it in novel ways to extend and enhance the lives of patients living with these devastating conditions.”
Kevin Kalish Bio
Kevin Kalish has over 15 years’ experience leading R&D, Program Management and Operations with Medtronic, Boston Scientific and Johnson and Johnson. Most recently he provided strategic leadership to the Transformative Solutions business unit at Medtronic. He received his MBA from Boston College, BSE/MSE from UMass Lowell and is Program Management Professional certified.
About EnClear Therapies
EnClear Therapies is a Cambridge (USA) based biotechnology company developing neurology-focused, device-based systems that remove toxic proteins as therapies for the treatment of neurodegenerative diseases and provide closed loop delivery & monitoring of cerebrospinal fluids (CSF). The company’s first products will target improving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP).
Shoreline Biotech Communications